List of bibliographic references
Number of relevant bibliographic references: 6.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 3 | Humans |
| 3 | Parkinson disease |
| 3 | Parkinson's disease |
| 2 | Male |
| 2 | Nervous system diseases |
| 2 | Treatment |
| 1 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (administration & dosage) |
| 1 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects) |
| 1 | Adult |
| 1 | Aged |
| 1 | Animal |
| 1 | Animal model |
| 1 | Animals |
| 1 | Antiparkinson Agents (adverse effects) |
| 1 | Antiparkinson Agents (pharmacokinetics) |
| 1 | Antiparkinson Agents (therapeutic use) |
| 1 | Apoptosis |
| 1 | Apoptosis (drug effects) |
| 1 | Apoptosis (genetics) |
| 1 | Caspase 3 |
| 1 | Caspases (metabolism) |
| 1 | Cause of Death |
| 1 | Cognition Disorders (diagnosis) |
| 1 | Corpus Striatum (drug effects) |
| 1 | Corpus Striatum (metabolism) |
| 1 | DNA Fragmentation |
| 1 | Deep Brain Stimulation (methods) |
| 1 | Deep brain stimulation |
| 1 | Disease Models, Animal |
| 1 | Dopamine Agents (administration & dosage) |
| 1 | Dopamine Agents (adverse effects) |
| 1 | Dyskinesia, Drug-Induced (etiology) |
| 1 | Enzymatic activity |
| 1 | Female |
| 1 | Follow-Up Studies |
| 1 | Human |
| 1 | Immunohistochemistry |
| 1 | In Situ Nick-End Labeling |
| 1 | Levodopa |
| 1 | Levodopa (adverse effects) |
| 1 | Levodopa (pharmacokinetics) |
| 1 | Levodopa (therapeutic use) |
| 1 | MPP+ |
| 1 | MPTP |
| 1 | Mice |
| 1 | Mice, Inbred C57BL |
| 1 | Middle Aged |
| 1 | Mortality |
| 1 | Mouse |
| 1 | Nerve Degeneration (pathology) |
| 1 | Neurons (drug effects) |
| 1 | Neurons (enzymology) |
| 1 | Neurons (pathology) |
| 1 | Neuropsychological Tests |
| 1 | Parkinson Disease (drug therapy) |
| 1 | Parkinson Disease (epidemiology) |
| 1 | Parkinson Disease (mortality) |
| 1 | Parkinson Disease (pathology) |
| 1 | Parkinson Disease (therapy) |
| 1 | Parkinson Disease, Secondary (chemically induced) |
| 1 | Pathogenesis |
| 1 | Postoperative Period |
| 1 | Predictive Value of Tests |
| 1 | Receptors, Dopamine (drug effects) |
| 1 | Receptors, Dopamine (metabolism) |
| 1 | Substantia Nigra (drug effects) |
| 1 | Substantia Nigra (enzymology) |
| 1 | Substantia Nigra (pathology) |
| 1 | Subthalamic Nucleus (physiology) |
| 1 | Subthalamic nucleus |
| 1 | Survival Rate |
| 1 | Terminology as Topic |
| 1 | Tyrosine 3-Monooxygenase (metabolism) |
| 1 | apoptosis |
| 1 | caspase‐3 |
| 1 | deep brain stimulation |
| 1 | dyskinesia |
| 1 | levodopa |
| 1 | mortality |
| 1 | motor complications |
| 1 | neurotoxicity |
| 1 | subthalamic nucleus |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/USA/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i -k "Yves Agid"
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i \
-Sk "Yves Agid" \
| HfdSelect -Kh $EXPLOR_AREA/Data/USA/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= USA
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Yves Agid
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
